

Subsequently, DEA, with FDA's and HEW's medical and scientific evaluation, issued a proposed regulation in the Fall of 1976. Lilly did not oppose that regulatory change, and the drug went on control March 14, 1977.

Scheduling Criteria

The provisions of the Controlled Substances Act that govern the scheduling of drugs are described in detail in Tab B of the Lilly Blue Book. However, we might note several points regarding the Health Research Group proposal to place propoxyphene in Schedule II. First, we want to review the findings of the Drug Enforcement Administration, made with the advice of HEW and this Committee's predecessor, placing propoxyphene products in Schedule IV. Second, we would like to discuss briefly the statutory criteria for placing a drug in Schedule II. Thus, based on the materials provided you and on information presented in last week's Senate hearings, we submit that propoxyphene does not meet the criteria for Schedule II.

When the DEA placed propoxyphene in Schedule IV, it did so on the basis of the following conclusions:

"1. Based on information now available, dextropropoxyphene has a low potential for abuse relative to the drugs or other substances currently listed in Schedule III.